Portola Pharmaceuticals   Print Page    Close Window

We are committed to providing the media with timely and accurate information.

Media Contact:
Patrick Ryan
Pure Communications
pryan@purecommunications.com

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
December 03, 2018Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching Among Patients with CTCL – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced updated interim results from the Company’s ongoing Phase 2a study of cerdulatinib, an investigational, oral Syk/JAK inhibitor, in patients with s... 
Printer Friendly Version
November 07, 2018Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
– Third Quarter Andexxa Product Revenues of $7.7 Million – – Company Improves Financial Expectations for 2018 Operating Expenses – – Conference Call Today at 4:30 p.m. ET – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2018 and provided a corporate update. “I am excited to join Portola at such a pivotal moment in the Company’s history. Having just compl... 
Printer Friendly Version
November 06, 2018Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following investor conferences in November and December: Credit Suisse’s 27th Annual Healthcare Conference on Tuesday, November 13, 2018, at 2:50 p.m. Mountain Time in Scottsdale, AZ. The Company will participate in a fireside chat at the conference, which will be webcast live and available for replay from the Investor Rel... 
Printer Friendly Version
November 01, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 26, 2018, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2018, the grant of an inducement stock option to purchase 250,000 shares of common stock and an award in the form of 125,000 restricted stock units to Scott Garland, the Company’s newly appointed president and chief executive officer.   The stock option... 
Printer Friendly Version
November 01, 2018Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting
– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies –              – Also Accepted: Two Posters on Andexxa® and an Oral Session on the Burden of Hospital Readmissions Due to Venous Thromboembolism Among Cancer Patients – SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with re... 
Printer Friendly Version
October 23, 2018Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended September 30, 2018, and provide a general business overview on Wednesday, November 7, 2018, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Wednesday, November 7, 2018, at 4:30 p.m. ET, can be accessed by phone by callin... 
Printer Friendly Version
October 09, 2018Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis
Highlights Proactive Risk Assessment in Hospitals as Opportunity to Optimize Patient Outcomes SOUTH SAN FRANCISCO, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its 2018 partnership with the World Thrombosis Day campaign to help raise global awareness of thrombosis. Observed annually on October 13, World Thrombosis Day is led by the International Society on Thrombosis and Haemostasis (ISTH), which has mobilized more than 1,500 partner ... 
Printer Friendly Version
September 25, 2018Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to cerdulatinib, an investigational, oral Syk/JAK inhibitor for the treatment of peripheral T-cell lymphoma (PTCL). “We are pleased that the FDA has granted cerdulatinib Orphan Drug Designation, as it recognizes its potential to provide a significant clinical benefit to a group of patients ... 
Printer Friendly Version
September 20, 2018Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer
– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful therapies, Avastin and Rituxan, during his tenure at Genentech –  SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of industry veteran Scott Garland as president and chief executive officer, effective October 8... 
Printer Friendly Version
September 11, 2018U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process
Action Date Set for December 31, 2018 SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement (PAS) filing for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. The PAS has been assigned a Prescription Drug User Fee Act (PDUFA) date of Dece... 
Printer Friendly Version
September 07, 2018Portola Pharmaceuticals Announces Executive Leadership Change
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September 21, 2018 to pursue opportunities outside the Company. The Company has engaged a leading executive search firm to assist management in identifying and recruiting a new chief commercial officer in parallel with the Company’s search for a chief executive officer. During the transition period, Mardi C.... 
Printer Friendly Version
September 05, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of Directors approved, effective as of August 31, 2018, the grant of an inducement stock option to purchase 87,500 shares of common stock and an award in the form of 30,000 restricted stock units to Ernest Meyer, the Company’s newly appointed executive vice president, chief human resources officer.   The... 
Printer Friendly Version
August 31, 2018Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA) for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. If approved, the PAS will allow for broad commercial launch of Andexxa in the United States. Andexxa received both U.S. Orphan Drug and FDA Breakth... 
Printer Friendly Version
August 30, 2018Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will participate in the following conferences in September: Citi’s 13th Annual Biotech Conference on Thursday, September 6, 2018 in Boston, MA. The Company will conduct one-on-one meetings with institutional investors at this conference.   Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018, at 2:15 p.m. Easte... 
Printer Friendly Version
August 09, 2018Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Conference Call Today at 8:30 a.m. ET – SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2018 and provided a corporate update. “The second quarter of 2018 brought a significant addition to our product suite with the U.S. Food and Drug Administration’s Accelerated Approval of Andexxa and the initiation of our Early Supply Program. Together with Bevyxxa, we now hav... 
Printer Friendly Version
August 09, 2018Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources Officer
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Ernie Meyer as executive vice president and chief human resources officer, effective August 20. As a member of the Executive Committee, Mr. Meyer will report to John T. Curnutte, M.D., Ph.D., interim co-president of Portola and head of research and development, with responsibility for leading the development and execution of the Company’s global human r... 
Printer Friendly Version
August 03, 2018U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ Andexxa
– Add-on payment to support patient access by providing additional Medicare reimbursement in the hospital setting – SOUTH SAN FRANCISCO, Calif. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote approved by the U.S. Food and Drug Administ... 
Printer Friendly Version
August 02, 2018Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended June 30, 2018, and provide a general business overview on Thursday, August 9, 2018, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call Details The live conference call on Thursday, August 9, 2018, at 8:30 a.m. ET, can be accessed by phone by calling (844) 452... 
Printer Friendly Version
July 27, 2018European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following Appeal
SOUTH SAN FRANCISCO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a final recommendation on betrixaban for the prevention of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death.  The CHMP maintained its negative opinion following a re-... 
Printer Friendly Version
July 03, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of Directors approved, effective as of June 29, 2018, the grant of an inducement stock option to purchase 87,500 shares of common stock and an award in the form of 25,000 restricted stock units to Glenn Brame, the Company’s newly appointed Senior Vice President, Technical Operations.   The stock option shal... 
Printer Friendly Version
June 25, 2018Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Glenn Brame as senior vice president of technical operations, effective immediately. Mr. Brame will report to Mardi Dier, interim co-president and chief financial officer, and will be responsible for leading the Company’s technical operations including process development, manufacturing, supply chain, quality assurance, and end-to-end process and platfo... 
Printer Friendly Version
June 05, 2018Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will present at the following conferences in June: Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018, at 9:20 a.m. Pacific Time in Rancho Palos Verdes, CA.   William Blair 38th Annual Growth Stock Conference on Wednesday, June 13, 2018, at 12:40 p.m. Central Time in Chicago, IL. Both presentations will be webca... 
Printer Friendly Version
June 04, 2018Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018
SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that William Lis has informed the Board of Directors of his plans to retire as Chief Executive Officer and member of the board. Mr. Lis will continue to serve as CEO and member of the board through August 1, 2018 to ensure a smooth transition, after which time he will remain in an advisory role. Mr. Lis joined Portola in 2008. The board has initiated an active search t... 
Printer Friendly Version
June 04, 2018New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib
– Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies – – New Signal in AITL; Five Complete Responses for a Complete Response Rate of 71 Percent – – Data to be Presented Monday, June 4, 2018 at ASCO and Friday, June 15, 2018 at EHA – SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from the Company’s ongoing Phase 2a study of cerdulatinib... 
Printer Friendly Version
May 24, 2018Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®
SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a $100 million milestone payment from HealthCare Royalty Partners (HCR) following the U.S. Food and Drug Administration (FDA) approval of Andexxa [coagulation Factor Xa (recombinant), inactivated-zhzo] on May 3, 2018. In February 2017, Portola entered into a $150 million royalty agreement with HCR in exchange for a tiered, mid-single-digit ... 
Printer Friendly Version
May 09, 2018Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
-- Conference Call Today at 4:30 p.m. ET -- SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended March 31, 2018 and provided a corporate update. “We achieved several major manufacturing and regulatory milestones this past year, including last week’s U.S. approval of Andexxa®. We are now concentrating the Company’s efforts on the successful launch of Andexxa and Bevyxxa®, which bo... 
Printer Friendly Version
May 03, 2018U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
– Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding – – Company to Host Conference Call on Friday, May 4, 2018 at 8:30 a.m. ET – SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients ... 
Printer Friendly Version
April 30, 2018Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2018, and provide a general business overview on Wednesday, May 9, 2018, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Wednesday, May 9, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-68... 
Printer Friendly Version
April 25, 2018Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
– Novel Oral SYK/JAK Inhibitor for Relapsed/Refractory B-cell and T-cell Cancers – SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with Non-Hodgkin Lymphoma (NHL), including B-cell NHL and relapsed/refractory peripheral T-cell lymphoma (PTCL), will be presented during a Poster Discussion Session at the 2018 American Society... 
Printer Friendly Version
April 04, 2018Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of Directors approved, effective as of March 30, 2018, the grant to four new employees of (i) inducement stock options to purchase an aggregate of 153,300 shares of common stock, including the grant of an inducement stock option to purchase 125,000 shares of common stock granted to John Moriarty, the Company... 
Printer Friendly Version
March 23, 2018Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for betrixaban for the prevention of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death. The Company intends to appeal the opinion and seek a re-exa... 
Printer Friendly Version
March 12, 2018Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding
– Excellent or Good Hemostasis Achieved in 83 Percent of Patients; Thrombotic Events Consistent with High Background Thrombotic Risk – – Data Presented in Late-Breaking Clinical Trial Session at American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18) – – Investor Webcast Scheduled for Today at 12:30 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from ANNEX... 
Printer Friendly Version
March 12, 2018Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of John B. Moriarty, J.D., as executive vice president and general counsel, effective immediately. Mr. Moriarty will report to William Lis, chief executive officer, and will serve as Portola’s chief legal officer, responsible for leading all legal, regulatory, governance and compliance initiatives. He also will be directly involved in strategic business t... 
Printer Friendly Version
March 06, 2018Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March: Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston. Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York. Both presentations will be webca... 
Printer Friendly Version
March 05, 2018Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa
Event Scheduled for Monday, March 12, 2018 at 12:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday, March 12, 2018 at the American College of Cardiology's 67th Annual Scientific Session & Expo (ACC.18), following the presentation of new interim data from the ongoing ANNEXA-4 Phase 3b/4 trial of the Company's investigational F... 
Printer Friendly Version
February 28, 2018Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
--Conference Call Today at 4:30 p.m. ET-- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a corporate update. “2017 was a year of significant achievement for Portola, highlighted by the FDA approval of our first medicine, Bevyxxa, and the regulatory application for FDA approval of our breakthrough-designated Factor Xa-inhibit... 
Printer Friendly Version
February 20, 2018Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a positive trend vote on the Marketing Authorisation Application (MAA) for andexanet alfa, a Factor Xa-inhibitor reversal agent, and a negative trend vote for betrixaban, an o... 
Printer Friendly Version
February 15, 2018Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2017, and provide a general business overview on Wednesday, February 28, 2018, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Wednesday, February 28, 2018, at 4:30 p.m. ET, can be access... 
Printer Friendly Version
January 22, 2018Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that an abstract detailing interim results from the Company’s ongoing Phase 3b/4 trial of its investigational Factor Xa reversal agent, andexanet alfa, has been accepted for oral presentation during a late-breaking clinical trial session at the American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18). The data will be presented on Monday, March ... 
Printer Friendly Version